35 related articles for article (PubMed ID: 37551467)
1. Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.
Mata DA; Lee JK; Shanmugam V; Marcus CB; Schrock AB; Williams EA; Ritterhouse LL; Hickman RA; Janovitz T; Patel NR; Kroger BR; Ross JS; Mirza KM; Oxnard GR; Vergilio JA; Elvin JA; Benhamida JK; Decker B; Xu ML
Histopathology; 2024 Jun; 84(7):1224-1237. PubMed ID: 38422618
[TBL] [Abstract][Full Text] [Related]
2. Analytical Validation of a 37-Gene Next-Generation Sequencing Panel for Myeloid Malignancies and Review of Initial Findings Incorporating Updated 2022 Diagnostic and Prognostic Guidelines.
Leung B; Aung H; Nandini A; Abdulrasool G; Lau C; Seymour L
J Mol Diagn; 2024 May; 26(5):399-412. PubMed ID: 38367765
[TBL] [Abstract][Full Text] [Related]
3. RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives.
Alawieh D; Cysique-Foinlan L; Willekens C; Renneville A
Blood Cancer J; 2024 Apr; 14(1):72. PubMed ID: 38658558
[TBL] [Abstract][Full Text] [Related]
4. Ring Chromosomes in Hematological Malignancies Are Associated with
Boyd RJ; Murry JB; Morsberger LA; Klausner M; Chen S; Gocke CD; McCallion AS; Zou YS
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001699
[TBL] [Abstract][Full Text] [Related]
5. Clinical Utility and Reimbursement of Next-Generation Sequencing-Based Testing for Myeloid Malignancies.
Soderquist CR; Freeman C; Lin WH; Leeman-Neill RJ; Gu Y; Carter MC; Stutzel KC; Sigcha E; Alobeid B; Fernandes H; Bhagat G; Mansukhani MM; Hsiao SJ
J Mol Diagn; 2024 Jan; 26(1):5-16. PubMed ID: 37981089
[TBL] [Abstract][Full Text] [Related]
6.
Gener-Ricos G; Bewersdorf JP; Loghavi S; Bataller A; Goldberg AD; Famulare C; Takahashi K; Issa GC; Borthakur G; Kadia TM; Short NJ; Senapati J; Carter BZ; Patel KP; Kantarjian H; Andreeff M; Stein EM; DiNardo CD
Leuk Lymphoma; 2024 Jun; ():1-5. PubMed ID: 38856690
[No Abstract] [Full Text] [Related]
7.
Mukherjee D; Lawal RA; Fitzhugh CD; Hourigan CS; Dillon LW
medRxiv; 2024 Feb; ():. PubMed ID: 38410480
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach.
Matthews A; Fenu E; Skuli SJ; Harris JC; Bagg A; Lai C
Leuk Lymphoma; 2024 Mar; ():1-4. PubMed ID: 38535517
[No Abstract] [Full Text] [Related]
9. TP53 mutation screening for patients at risk of myeloid malignancy.
Mukherjee D; Lawal RA; Fitzhugh CD; Hourigan CS; Dillon LW
Leukemia; 2024 May; ():. PubMed ID: 38796530
[No Abstract] [Full Text] [Related]
10. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.
Duncavage EJ; Tandon B
Int J Lab Hematol; 2015 May; 37 Suppl 1():115-21. PubMed ID: 25976969
[TBL] [Abstract][Full Text] [Related]
11. Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.
Yang F; Anekpuritanang T; Press RD
Mol Diagn Ther; 2020 Feb; 24(1):1-13. PubMed ID: 31848884
[TBL] [Abstract][Full Text] [Related]
12. [High-Throughput Sequencing Technology for Detection of Gene Mutations in Myeloid Malignancies and Its Clinical Prognostic Significance].
Ouyang M; Jiang B; Zhang MX; Hu WQ; Shi L; Liu JX; Zhang YY; Wang CJ; Wang F; Zhang Y; Ren HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Aug; 31(4):992-998. PubMed ID: 37551467
[TBL] [Abstract][Full Text] [Related]
13. Gene mutation analysis using next-generation sequencing and its clinical significance in patients with myeloid neoplasm: A multi-center study from China.
Li J; Pei L; Liang S; Xu S; Wang Y; Wang X; Liao Y; Zhan Q; Cheng W; Yang Z; Tang X; Zhang H; Xiao Q; Chen J; Liu L; Wang L
Cancer Med; 2023 Apr; 12(8):9332-9350. PubMed ID: 36799265
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of Gene Mutation Characteristics and Prognosis of Elderly Patients with Acute Myeloid Leukemia].
Zhou NC; Li GH; Qin WW; Wang WQ; Guo HP; Liu C; Liu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):755-759. PubMed ID: 35680801
[TBL] [Abstract][Full Text] [Related]
15. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
Sasaki K; Kanagal-Shamanna R; Montalban-Bravo G; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Patel K; Soltysiak KA; Cortes J; Kantarjian HM; Garcia-Manero G
Cancer; 2020 Feb; 126(4):765-774. PubMed ID: 31742675
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]